• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Umoja Biopharma

Monday, June 03, 2024
CP
Cell and Gene Therapy and Genome Editing
Umoja is a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of CAR T cell therapies in oncology and autoimmunity. Our flagship technology is VivoVec, an in vivo delivery system that generates CAR T cells directly in a patient's body without the current complications and expense of today's first generation ex vivo CAR T cell therapies.
Umoja Biopharma
Company Website: http://umoja-biopharma.com
Lead Product in Development: UB-VV111, a gene therapy generating CD19 CAR T cells in vivo

Company HQ City

Seattle

Company HQ State

Washington

Company HQ Country

United States

CEO/Top Company Official

Andrew Scharenberg

Development Phase of Primary Product

Pre-Clinical
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS